INTRODUCTION
Glioblastoma multiforme (GBM), the most common and aggressive primary brain tumor, is diagnosed in approximately 10,000 new cases per year in the USA (1), with a median survival of approximately 14 months (2) . GBM is characterized by cellular heterogeneity, rapid proliferation, angiogenesis and extensive invasion (3) . Concomitant high proliferation and infiltration constitutes the major challenge for GBM therapy, because even with extensive resection tumor cells are left behind in the brain, leading to recurrence. Angiogenesis constitutes a major advantage to rapidly growing tumors by providing oxygen and nutrients, yet anti-angiogenic treatment may paradoxically increase invasiveness (4) . Thus novel The 3'-UTR encompassing the target sequence for miR-1 of ANXA2 cDNA were cloned into the pMIR-REPORT vector (Ambion). For the mutated construct of the QuickChange Site-Directed Mutagenesis Kit (Stratagene) was used according to manufacturer's protocol to alter the miR-1 seed sequence. Luciferase reporter assays were performed as previously described (23) using luciferase reagent (Promega). EVs loaded with miR (NC or miR-1) were used for luciferase assays at a concentration of500 EVs per cell.
Cells were treated with EVs 24h prior to reporter transfection. Transfection (25-75 nmol/L) of negative control (NC) and pre-miR-1 (miR-1) or pre-miR-1 FAM labeled (miR-1 FAM) (Ambion), or pMIR-REPORT was done with Lipofectamine2000 (Invitrogen).
In vivo studies
Female immunodeficient mice were purchased from Taconic. For all studies the mice were housed in animal facility at the OSU in accordance with all NIH regulations. All protocols were approved by the OSU Institutional Animal Care and Use Committee. In vivo studies were performed as previously 
In vitro 2D and 3D assays
3D spheroid migration assay in collagen matrix and its quantification were performed as previously described (23) . The vessel-forming ability of HBMVEC was characterized in vitro using a Matrigel assay (25) (see Supplemental Experimental Procedures). Propidium iodide exclusion and flow cytometry-based cell-cycle analysis was carried out using the Becton Dickinson FACSCalibur system.
Purification of EVs
To isolate EVs, U87 and X12 cells were cultured for 2 days in EV free medium without antibiotics. The conditioned media were collected and EVs were isolated by differential centrifugation as previously described (26) 
(see Supplemental Experimental Procedures).

Proteomic analysis
All mass spectra were acquired at the Bioproximity LLC. Proteins were prepared for digestion using the filter-assisted sample preparation (FASP) method (27) 
(see Supplemental Experimental
Procedures).
Protein extraction and Western blot analysis was done as described previously (28) . Representative images from two or three independent experiments are shown. Antibodies used were as follows: ANXA2
(1:1000, Santa Cruz), CD133 (1:1000, Amersham), BMI1 and GFAP (1:1000, Millipore) Akt and pAKT Ser473, ERK and pERK Thr202/Tyr204Y, JNK and pJNK Thr183/Tyr185, MET and p-MET Tyr1234/1235, EGFR, PDGFRA, SUZ12, FASN (1:2000, Cell Signaling), YWHAZ and CD63 (1:1000, Santa Cruz), CD9 (1:500, Novus) and a Tubulin (1:10,000, Sigma Aldrich).
Microscopy
All fluorescent and light microscopy based assays were monitored using a Zeiss LSM510 confocal microscope system (Carl Zeiss Inc.).Ultrathin frozen sections and immunogold labeled CD63 antibody were prepare in Cellular Neuroscience Core Laboratory. The Transmission Electron microscopy Tecnai G² Spirit BioTWIN or with AMT 2k CCD camera was used to analyze EVs stained with immunogold labeled anti CD63 antibody in Electron Microscopy Facility at Harvard Medical School.
Quantitative PCR
Total RNA was extracted using Trizol (Invitrogen) and treated with RNase-free DNase (Qiagen). Mature and pri-miR expression analysis by qPCR was carried out using the miR real-time PCR detection kit (Applied Biosystems) as described (23) . Messenger RNA expression analysis was carried out using Power SYBR Green (Applied Biosystems). RNA concentration was quantified using Nanodrop RNA 6000 nanoassays and analyzed using Agilent 2100 Bioanalyzer total and Pico RNA platform.
Data and Statistical Analysis
All microscopy-based assays were edited/quantified using ImageJ (http://rsb.info.nih.gov.ezpprod1.hul.harvard.edu/ij/), including the Analyze Skeleton plugin and Analyze Particles function of binary images with automatic threshold. Pathway analysis was performed using Ingenuity Pathways or Graph Pad Prism 6 software. P < 0.05 was considered statistically significant (single asterisks in the
Figures), and P < 0.01 was strongly significant (double asterisks).
RESULTS
MiR-1 is downregulated in human GBMs and in GBM cells during migration in vitro.
Our previously published microarray study indicated that miR-1 levels were significantly reduced when compared to adjacent brain tissue from the same individual (29) . More recently, our group also demonstrated, that the expression of miR-1 was shut off over a three day in vitro spheroid migration assays (23) . In fact, miR-1 was one of five miRs downregulated in both arrays (Fig.1A) . To validate the microarray data from the first study (29) , we tested miR-1 expression in a panel of eight patient GBM samples with matched adjacent brain by quantitative real time (qPCR) (Fig.1B) . This confirmed that there was significant downregulation of miR-1 in GBM compared to surrounding brain. The microarray data from the second study (23) was also validated by showing that miR-1 was downregulated in U87 and X12
GBM cells during a three days migration assay (Fig.1C) . Finally, we assessed miR-1 expression in nonmalignant astrocytes, neuro-glia, and endothelial brain microvasculature, as well as in a broad panel of Based on the above findings, we hypothesized that miR-1 may act as a tumor suppressor. To investigate the function of miR-1 in glioblastoma we stably expressed miR-1 using a lentiviral expression vector.
U87 flank xenografts expressing miR-1 were significantly smaller than controls ( Fig.2A) and there was significant reduction in the proliferation index ( Supplementary Fig.S1A ). The decreased growth was not due to apoptosis because cleaved Caspase-3 was not significantly elevated in cells expressing miR-1 ( Supplementary Fig.S1B ). Interestingly, the recruitment of endothelial cells measured by CD31 staining was significantly decreased, suggesting that impaired angiogenesis is at least partially responsible for the observed growth inhibition mediated by miR-1 in vivo (Supplementary Fig.S1C ). Next, we evaluated GBM cell tumorigenicity by intracranial implantation of U87 and X12 cells stably expressing miR-1.
These tumors were significantly smaller than controls (Fig.2B) . Survival analysis demonstrated a significantly better outcome of animals injected with miR-1 expressing cells. In U87 cells we observed a substantial subgroup of long-term survivors (Fig.2C) . Analysis of neovascularization was performed on symptomatic animals at 5 weeks (U87) or 7 weeks (X12) after tumor implantation. MiR-1 expressing tumors displayed reduced CD-31 staining, with shorter average branch length and fewer prominent branches (Fig.2D) . These results were confirmed by lectin staining (Supplementary Fig.S1D ). S2C ) and 3D assays ( Supplementary Fig.S2D ). Moreover, miR-1 expression reduced infiltration in a 3D collagen matrix with cells displaying a cuboidal, non-invasive morphology (Fig.3A with insets) .
Reduced migration was also confirmed by a wound healing assay ( Supplementary Fig.S2E ). In contrast to the effects on migration, there was no effect of miR-1 on the cell cycle (with the exception of a small but non-significant increase in the apoptotic fraction in U87 cells ( Supplementary Fig.S2F ). Interestingly, GBM cells cultured in stem-like conditions had significantly impaired neurosphere formation upon miR-1 expression, both in stably infected ( Fig.3B ) and transiently transfected cells ( Supplementary Fig.S2G ).
Therefore, miR-1 expression reduced GBM cell to cell and cell to matrix adhesion leading to reduced neurosphere sizes and inhibited in vitro invasion.
The above results showed that miR-1 expression led to a variety of phenotypic changes. We thus hypothesized that miR-1 could be de-regulating multiple signaling pathways linked to GBM progression.
We thus investigated the status of such oncogenic signaling in GBM cells transfected with miR-1 and cultured either as monolayers or in "stem-like" neurosphere conditions. We observed reduced level of phospho AKT (X12 only) but no changes in phospho-ERK levels (Fig.3C ). However phospho-JNK levels were consistently reduced, especially in stem-like conditions (where basal phospho-JNK levels were elevated). Stem-like culture conditions caused a significant increase in levels of the putative glioma stem cell marker CD133, as well as an increase in stem cell self-renewal factorsBMI1 and SUZ12. Levels of the astrocyte lineage marker GFAP were significantly reduced under these neurosphere culture conditions. MiR-1 transfection abrogated these effects of neurosphere culture, and reduced levels of CD133, BMI1 and SUZ12, while increasing levels of differentiation marker GFAP (Fig.3D) .
Interestingly, cells transferred from monolayer culture to stem-like conditions had significantly reduced endogenous expression of miR-1 ( Supplementary Fig.S2H ). Finally, we analyzed the effect of miR-1 expression on cellular receptors known to play a crucial role in GBM cell biology. We observed elevated levels of and the known miR-1 target MET (30, 31) under neurosphere conditions. As expected, pro- MET, MET and phospho-MET levels were significantly reduced by miR-1 expression. Also EGFR level was diminished in miR-1 expressing cells, while PDGFR level was increased in U87 and reduced in X12 cells, suggesting cell type specific effects (Fig.3E) . These results thus indicated that miR-1 inhibited multiple signaling pathways, associated with "stemness" of GBM stem-like cells.
MiR-1 expression blocks EV stimulation of GBM invasion and growth. The findings showing
reduced invasion and angiogenesis in miR-1 expressing cells suggested that it influences the tumor microenvironment. Thus we hypothesized that miR-1 could be acting on intercellular communication via
EVs which have been shown to be important mode of release biomolecules by GBM cells (13) . To investigate the role of paracrine communication via EVs in neovascularization, we used a tube formation assay using recipient brain microvascular endothelial cells (HBMVEC) (32) . These cells form tube-like structures in growth factors supplemented medium (Fig.4A , left panels). HBMVEC treated with GBM neurospheres-derived EVs (donor cells) formed significantly longer and more branched tube-like structures than controls. This effect was significantly reduced in the presence of EVs collected from miR-1 expressing neurospheres compared with controls (Fig.4A, right panels ).
Next, we tested the effect of EVs on migration of stem-like neurospheres. We found that the presence of EVs (collected from donor neurospheres) strongly promoted recipient cell migration in spheroid assays (Fig.4B ). This effect was significantly diminished using EVs collected from miR-1 expressing donor cells, both in terms of distance travelled by the cells and number of cells leaving the spheroid core (Fig.4B, Supplementary Fig. S3A ). We also found that EVs derived from control neurosphere donor cells promoted neurosphere formation of recipient cells; while EVs collected from miR-1 expressing donor cells had no significant effect (Fig.4C) . Expression of miR-1 in recipient cells also prevented EV promotion of neurosphere formation ( Supplementary Fig. S3B ). Thus expression of miR-1 prevents EV stimulation of angiogenesis, invasion and neurosphere formation in recipient cells. 
As a control, we confirmed that miR-1 expression did not alter expression of the EV marker CD63 (Supplementary Fig. S3C ). Interestingly, miR-1 expression did lead to a small but significant decrease in EV size (Supplementary Figure S3D) , but miR-1 expression did not alter the number of EVs secreted by GBM cells (Supplementary Figure S3E) . Additional characterization of EVs released by GBM stem-like cells showed that EV fractions lacked larger RNAs compared to total cellular RNA ( Supplementary Fig.   S3F ); and EVs collected from miR-1 expressing cells showed increased levels of RNAs smaller than 40nt (Supplementary Fig. S3G ). Therefore, we conclude that observed effects of EVs derived from miR-1 expressing donor cells on recipient cells were more likely due to such EVs cargo and not to a difference in EV quantity or release from donor cells.
MiR-1 is transferred between GBM cells by EV transport.
We next asked whether miR-1 itself could be transferred by GBM-derived EVs. To visualize EV transfer we created cell lines expressing RFP-CD63 and used them as donor cells. After treatment with EVs derived from RFP-CD63 expressing cells we detected RFP inside GFP-labeled recipient cells (Supplementary Fig. S4A ). To visualize miR-1 transfer, we used U87 cells co-transfected with FAMlabeled miR-1 and RFP-labeled CD63 as EV donor cells. We observed that a substantial fraction of FAMmiR-1 co-localized with RFP-CD63, but also that a fraction of FAM-miR-1 remained in the donor cells cytoplasm (Fig.5A, upper panels) . EVs released by FAM-miR-1/RFP-CD63 transfected cells were then added to recipient, non-fluorescent U87 cells. We observed partial co-localization of FAM-miR-1 with RFP-CD63 in the cytoplasm of recipient cells (Fig.5A, middle panels; Supplementary Fig.S4B ). A similar result was observed in co-culture experiments (Fig.5A , lower panels) strongly suggesting that miR-1 can be transferred between cells through EVs. To survey the transfer of miR-1 from donor to recipient cells, we performed qPCR analysis on RNA extracted from donor cells (U87, X12), as well as their corresponding EVs and recipient cells. We observed a significant increase of mature miR-1 levels in all tested samples (Fig.5B) , but the primary transcript was not detected in recipient cells (Supplementary Fig.   S4C ). This suggests that the observed increase of mature miR-1 levels in recipient cells is due to EV CAN-13-2650 transfer, not to increased endogenous miR-1 expression. These observations support the notion that the miR-1 dependent paracrine effect is at least partially mediated via EV transfer.
MiR-1 overexpression affects the EV protein cargo by direct and indirect targeting.
The EV-mediated phenotype observed in recipient cells suggested an active role of the EV molecular cargo. Since microRNAs modulate the cellular proteome, we characterized the EV protein cargo in miR-1 expressing cells by global mass-spectrometry analysis of EVs. We identified 1038 proteins of which 462 were significantly downregulated and 11 upregulated in miR-1 expressing U87 cells compared with controls ( Fig.6A , Table S1 ). "RNA binding" and "Vesicles" were among the most abundant functional annotations among these proteins and enzymes and transporters were among the most prominent types of proteins found in GBM EVs ( Supplementary Fig. S5A, B) . The most abundant networks identified were cancer-related and cell survival was among the most significant molecular process connected to proteins found in GBM EVs (Table S2) . Among identified proteins, 205 were putative targets of miR-1 and among these 84 were downregulated in EVs collected from miR-1 expressing cells ( Supplementary Fig.   S5C , D). This was confirmed for three putative targets by Western analysis, which showed that ANXA2, FASN and 14-3-3ȗ were significantly reduced in EVs collected from miR-1 expressing cells (Fig.6B) .
These results thus showed that miR-1 expression led to changes in the EV proteome, linked to cancerrelated signaling networks.
Interestingly, ANXA2 was identified as the most abundant EV protein (Table 1 ) and its mRNA 3'UTR contains a conserved miR-1 target site (Supplementary Fig. S5E ). ANXA2 was previously implicated as an important pro-oncogenic factor in GBM, promoting proliferation, invasion and angiogenesis (20) . The observed miR-1 dependent phenotype was thus consistent with ANXA2 downregulation, providing a biologic rationale for exploring a link between miR-1 and ANXA2. We thus proceed to verify the link between miR-1 and ANXA2. The level of ANXA2 in two cell lines stably expressing miR-1 was significantly reduced compared with that of controls (Fig.6C) . Similarly downregulation of miR-1 was observed in a panel of five cell lines transfected with miR-1 ( Supplementary Fig. S5F ). Direct targeting of ANXA2 by miR-1 was demonstrated using a luciferase reporter assay with the 3'UTR of ANXA2 and, in addition, mutagenesis of the predicted miR-1 binding site abolished the suppression of luciferase by miR-1 (Fig.6D, Supplementary Fig. S5E ). ANXA2 in conditioned medium was detected almost exclusively in the EV compartment (Supplementary Fig. S5G ) and stem-like culture conditions caused a significant increase in ANXA2 levels, which was reflected in its EV content. This was strongly reduced by miR-1 expression (Supplementary Fig. S5H ). This data thus confirmed that ANXA2 was a direct mRNA target of miR-1 and that miR-1 expression resulted in decreased ANXA2 levels in EVs.
To further demonstrate the functional consequences of EV-mediated miR-1 transfer, we analyzed its effect on ANXA2 in recipient cells. When purified EVs collected from miR-1 expressing cells were added to recipient cells, there was a significant reduction of ANXA2 and MET proteins, when compared to treatment with control EVs (Fig.6E) . Since the endogenous level of mRNAs for these genes did not significantly change (data not shown), the observed downregulation was most likely due to expected microRNA-mediated effects during translation. The functionality of miR-1 in recipient cells was demonstrated by a luciferase assay with the ANXA2 3'UTR reporter (Fig.6F) , showing a significant decrease in luciferase activity in cells treated with EVs from miR-1 expressing cells. The effect was abolished by mutations in the miR-1 site of the ANXA2 3'UTR. These results strongly suggested that miR-1 delivered by EVs is functional and can reduce ANXA2 levels in recipient cells by direct targeting of ANXA2 3'UTR.
To demonstrate the clinical relevance of miR-1/ANXA2 targeting in GBM, we established that ANXA2 mRNA levels were elevated in patient GBM samples and were also significantly inversely correlated with miR-1 (Fig.6G) . Moreover, Western analysis showed a significant upregulation of ANXA2 protein in brain tumor samples (Fig.6H) . Also, according to Oncomine and TCGA databases, GBMs are characterized by high expression of ANXA2 mRNA (Supplementary Fig. S5I ) and its low expression is significantly associated with better outcome (Fig.6I) . Thus, these data strongly implicate ANXA2 as a significant player in GBM biology and identify miR-1 as an important direct regulator of ANXA2, both in tumor cells and in the tumor microenvironment. proteins in EVs collected from miR-1 overexpressing cells. Based on the fact that the phenotype observed upon miR-1 expression is consistent with reduced levels of ANXA2, we hypothesized that this protein is not only the direct target of miR-1 but also its major effector in GBM cells. Expression of miR-1 and ANXA2 were inversely correlated in human GBM samples, and miR-1 directly binds to site on the ANXA2 3'UTR leading to repression of ANXA2 protein levels. Furthermore, bioinformatic analysis revealed that miR-1 putatively targets several proteins functionally related to ANXA2 (Fig.6J ) in addition to previously published targeting of MET mRNA. MiR-1 deregulated the protein cargo of GBM-derived EVs without significant differences in EV secretion or uptake, suggesting that observed phenotype is in fact mediated by differences in the content of EVs molecular cargo, including ANXA2. These data strongly suggest a mechanistic link between miR-1 and ANXA2 suppression on GBM cells and their microenvironment.
It has been postulated that miR replacement approaches have strong therapeutic potential because of the fact that single miRs can regulate multiple oncogenic pathways that are commonly deregulated in cancer (42) . Our report provides novel evidence that miR-1 is inactivated in GBM. E. Invasiveness in vivo was determined by co-injection of non-invasive RFP-Gli36 cells with invasive GFP-X12 cells stably expressing either pCDH-GFP control vector (pCDH) or pCDH-GFP miR-1 vector (pCDH miR-1). Scale bars: 100ȝm. Data are expressed as mean ±SD, *P < 0.05. A. Migration of GBM cells was measured by a spheroid dispersal assay. Representative images of spheroid migration of U87 (upper panels) and X12 (lower panels) GBM cells transiently transfected with either negative control miR (NC) or miR-1. Scale bars: 100ȝm (upper panels) and 200ȝm (lower panels). The insets in all panels are magnified x 2.5. Migratory zones were quantified after indicated time, expressed as mean ± SD. *P < 0.05.
B.
Neurosphere formation capacity was determined by a self-renewal assay. Representative images of U87 and X12 cells stably expressing pCDH-GFP control vector (pCDH) or pCDH-GFP miR-1 vector (pCDH miR-1). Scale bars: 200ȝm. Neurosphere frequency were quantified after 72h, expressed as mean ± SD. *P < 0.05. C. Cellular signaling was monitored by Western blot analysis of U87 and X12 cell lines cultured as monolayer (M) or stem cell-like neurospheres (SC). Cells were transiently transfected with either negative control miR (NC) or miR-1. Cell lysates were blotted with anti-phospho-specific antibodies, and compared with total kinase antibodies. Tubulin was used as a loading control.
D.
Stemness was monitored by Western blot analysis of U87 and X12 cell lines cultured as monolayer (M) or stem cell-like neurospheres (SC). Cells were transiently transfected with either negative control miR (NC) or miR-1. Cell lysates were blotted with indicated antibodies. Tubulin was used as a loading control.
E. Expression of cellular receptors was monitored by Western blot analysis of U87 and X12 cell lines cultured as monolayer (M) or stem cell-like neurospheres (SC). Cells were transiently transfected with either negative control miR (NC) or miR-1. Cell lysates were blotted with anti-phospho-specific antibodies and with total protein antibodies. Tubulin was used as a loading control. A. Tube-like formation of HBMVEC in unsupplemented (NB-) and supplemented (NB+) Neurobasal medium and upon the presence of EVs was monitored by 3-D Matrigel assay. EVs were collected from U87 (EV U87) and X12 (EV X12) cells stably infected with either pCDH-GFP control vector (pCDH) or pCDH-GFP miR-1 expressing vector (pCDH miR-1). Representative images are shown. Scale bars: 250ȝm. Data are expressed as mean ±SD, *P < 0.05.
B.
Migration of GBM stem-like neurospheres upon the presence of NB-medium neurospheres upon the presence of EVs was measured by spheroid dispersal assay. ANXA2 3ƍUTR (mut) was used as a control. Luciferase levels are expressed as mean relative to controls ± SD; **P < 0.01.
E.
Effects of EV-carried miR-1 on the expression of ANXA2 and MET were validated by Western blotting analysis. U87 and X12 cells were exposed to the presence of EVs derived from corresponding cells transiently transfected with either negative control miR (NC) or miR-1 oligonucleotides. Cell lysates were blotted with antibodies against ANXA2, MET and tubulin as a loading control.
F. Direct targeting of ANXA2 3ƍUTR by EV-carried miR-1 was validated using luciferase/3'UTR reporter assay. U87 and X12 cells were exposed to the presence of EVs derived from corresponding cells transiently transfected with either negative control miR (NC) or miR-1 and after 24h transfected with luciferase/ANXA2 3ƍUTR wild type (wt) and mutant (mut) reporter vector. Luciferase levels are expressed as mean relative to controls ± SD; **P < 0.01.
G.
Relative expression of miR-1 (left) and ANXA2 mRNA (right) levels were validated by qPCR in GBM brain tumor (BT) specimens vs. matching brain adjacent to tumor (BAT) (n = 8). Values are expressed as mean relative miR-1 expression level ± SD.
H. ANXA2 protein level was validated in GBM by Western blotting analysis. Cell lysates from GBM brain tumor (BT) specimens vs. matching brain adjacent to tumor (BAT) (n = 3) were blotted with antibodies against ANXA2. Tubulin was used as a loading control. List of top five de-regulated EV proteins identified by mass spectrometry in EVs derived from U87 cells transfected with either negative control (NC) or miR-1. The base two log of the ratio specifies the difference in number of peptide hits between the groups.
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